Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline plc

http://www.gsk.com

Latest From GlaxoSmithKline plc

Lower Reimbursement For Accelerated Approval Drugs May Get Push From ICER

ICER President Steve Pearson expresses interest in setting drug costs for accelerated approval drugs low with price increases based on confirmatory evidence ahead of upcoming white paper from the group.

Pricing Debate Cost Effectiveness

Could Start-Up Adagio’s COVID-19 Antibody Have A Fighting Chance?

The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.

Coronavirus COVID-19 Financing

Worldwide Novel Drug Launches Soared Amid Pandemic

The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.

Companies Commercial

EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States

After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.

Coronavirus COVID-19 Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • ABR Development
    • Cellzome
    • Corixa Corporation
    • Fountain Acquisition Corporation
    • Genelabs Technologies, Inc.
    • GlycoVaxyn AG
    • Human Genome Sciences, Inc.
    • ID Biomedical Corporation
    • Okairos AG
    • PRAECIS Pharmaceuticals, Inc.
    • Reliant Pharmaceuticals
    • Sirtris Pharmaceuticals
    • Sitari Pharmaceuticals, Inc.
    • SmithKline Beecham
    • Stiefel Laboratories, Inc.
    • Tesaro, Inc.
    • ViiV Healthcare
UsernamePublicRestriction

Register